leadf
logo-loader
viewMindset Pharma Inc
(
CSE:MSETOTCQB:MSSTFFRA:9DF
)

Mindset Pharma selects two indications to target for its lead clinical candidate MSP-1014

Mindset Pharma Inc (CSE:MSET, OTCQB:MSSTF, FRA:9DF) (CSE:MSET) (OTCQB:MSSTF) (FRA:9DF) CEO James Lanthier and Chief Scientific Officer Joseph Araujo joined Proactive to speak about how the group has selected Treatment-Resistant Depression (TRD) and End of Life Cancer Angst as initial target indications for its lead clinical candidate MSP-1014.

The company said MSP-1014 is a novel patent-pending drug candidate that, based on preclinical data, shows potential to be a safer second-generation psilocybin-like therapy with decreased potential for side effects.

Quick facts: Mindset Pharma Inc

Follow
CSE:MSET

Price: 0.84 CAD

Market Cap: $60.66 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of named herein, including the promotion by the Company of in any Content on the Site, the Company receives from said issuer annual cash...

FOR OUR FULL DISCLAIMER CLICK HERE

Mindset Pharma say latest results further validate lead candidate's...

Mindset Pharma Inc (CSE:MSET, OTCQB:MSSTF, FRA:9DF) (CSE:MSET) (OTCQB:MSSTF) (FRA:9DF) CEO James Lanthier and Chief Scientific Officer Joseph Araujo tell Proactive that its lead candidate MSP-1014 was comparable to psilocybin assessed using a drug discrimination assay. Araujo and Lanthier...

6 days, 11 hours ago

2 min read